New study data indicate that intravenous iron may improve health-related quality of life in women who have iron deficiency anaemia caused by abnormal uterine bleeding. In addition, treatment with ferumoxytol, where oral iron has previously been unsuccessful, increases haemoglobin levels in this patient group, according to the researchers.

Iron deficiency anaemia is associated with colorectal cancer1. Several studies have highlighted the important relationship between preoperative anaemia and poor postoperative outcomes for these patients1,2. One cause of this relationship may be increased perioperative allogeneic red blood cell transfusion (ARBT), as a result of preoperative anaemia. The use of ARBT has been independently linked with impaired surgical and oncological outcome3.

Blood transfusion avoidance is an important goal in the management of patients with end-stage renal disease (ESRD). However, despite the increased use of agents to treat anaemia and iron deficiency over the last 15 years, the proportion of these patients receiving blood transfusions has doubled. 

Study results have revealed that ferumoxytol may be a suitable treatment alternative to iron sucrose for patients with iron deficiency anaemia when oral iron is unsatisfactory or intolerable. The authors also suggest that ferumoxytol has the potential to increase treatment compliance in this patient population.

A new study demonstrates that there is a high prevalence of anaemia in patients with advanced chronic kidney disease, which increases in the later stages of the disease. The authors suggest that control of anaemia may be achieved with moderate doses of erythropoietin stimulating agent (ESA) and iron therapy, as per current guidelines.

Recent research has ascertained that, although iron deficiency is common in patients with chronic obstructive pulmonary disease (COPD), it is not routinely tested for or treated. It has also been shown that treating these patients with erythropoietin stimulating agents (ESAs) or intravenous iron not only corrects the iron deficiency but also improves symptoms of dyspnoea.

Intravenous iron may improve erythroid recovery in patients treated with DA after haematopoietic cell transplantation (HCT). Darbepoetin alfa (DA) helps to ensure full erythroid reconstitution after autologous HCT when started on day 28 post-transplant, a new study indicates.


Subscribe to RSS - Treatment